Companies: 10,795·Total market cap: $144.5T
Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARSNASDAQHealthcare● Active
$59.53
+$0.25(+0.41%)
Market Cap$2.6B
P/E Ratio
52W High$85.25
52W Low$38.51
SEC Filings

Tarsus Pharmaceuticals, Inc. (TARS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001819790 · TARS · NASDAQ · as of Jun 8, 2026

Filing snapshot

617
Total Filings
SCHEDULE 13G
Latest Form
2026-05-15
Most Recent
2020
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001819790 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-23
Fiscal Year End
Feb 23, 2026
Accession No.
0001819790-26-000019
Primary Document
tars-20251231.htm
Source: data.sec.gov · CIK 0001819790 · Accession 0001819790-26-000019

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
8-KCurrent Report
8-K
2026-05-06Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-08
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-06
View
10-QQuarterly Report
10-Q
2026-05-06
View
8-KCurrent Report
8-K
2026-05-06
View
ARSARS
ARS
2026-04-28
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-28
View
DEF 14AProxy Statement
DEF 14A
2026-04-28
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-27
View
S-8Employee Stock Plan Registration
S-8
2026-02-23
View
10-KAnnual Report
10-K
2026-02-23
View
8-KCurrent Report
8-K
2026-02-23
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-02-20
View
8-KCurrent Report
8-K
2026-02-18
View
Showing 1–15 of 237 filingsForm 4 / 144 hidden· 617 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001819790  |  Exchange: NASDAQ · Healthcare

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has submitted 617 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001819790, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Tarsus Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Tarsus Pharmaceuticals, Inc. 10-K was filed on 2026-02-23 for fiscal year ending 2026. Historical TARS 10-K annual reports are available from 2020 through 2026.

Investors researching Tarsus Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

TARS SEC Filings · 8 questions

Tarsus Pharmaceuticals, Inc. (TARS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 617 filings and access original documents at no cost. Tarsus Pharmaceuticals, Inc.'s CIK is 0001819790.

TARS SEC filingsTarsus Pharmaceuticals, Inc. SEC documentsfind TARS 10-K